Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.

ABSTRACT:

Background

Advanced or metastatic esophageal squamous cell carcinoma (ESCC) is associated with poor prognosis; new first-line systemic treatment options are needed. Combining immuno-oncology therapies with standard chemotherapy may represent a promising approach for the treatment of solid tumors. Results from a Phase Ib study evaluating durvalumab with tremelimumab and chemotherapy in patients with advanced or metastatic ESCC are reported.

Methods

Adults with advanced or metastatic ESCC who were candidates for first-line platinum-based chemotherapy received durvalumab 1500 mg (Day 1), tremelimumab 75 mg (Day 1), cisplatin 80 mg/m² (Day 1) and 5-fluorouracil (5-FU) 800 mg/m² (Days 1-5) in 28-day cycles until disease progression or discontinuation due to

SUBMITTER: Lee DH 

PROVIDER: S-EPMC10469840 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature